tiprankstipranks
Viracta Therapeutics appoints Faerm as Chief Financial Officer
PremiumThe FlyViracta Therapeutics appoints Faerm as Chief Financial Officer
1M ago
Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
PremiumThe Fly
Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
2M ago
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
PremiumPress Releases
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
3M ago
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
PremiumThe FlyOppenheimer biotech/healthcare analysts hold analyst/industry conference call
4M ago
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
PremiumThe Fly
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
4M ago
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
PremiumThe Fly
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
4M ago
Viracta Therapeutics announces ODD granted by U.S. FDA to nana-val
PremiumThe FlyViracta Therapeutics announces ODD granted by U.S. FDA to nana-val
6M ago
Viracta Therapeutics granted orphan status for carcinoma treatment
PremiumThe Fly
Viracta Therapeutics granted orphan status for carcinoma treatment
6M ago
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
PremiumPress Releases
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100